Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL. (Q38754124)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924459%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924459%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

main subject

vascular calcification

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924459%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Emma Harper

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924459%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Hannah Forde

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924459%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Colin Davenport

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924459%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Diarmuid Smith

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924459%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Philip M Cummins

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924459%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

24 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924459%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

published in

Vascular Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924459%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924459%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

30-40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924459%20AND%20SRC:MED&resulttype=core&format=json

Vascular calcification and osteoporosis--the nature of the nexus.

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Effect of calcification on in vivo mechanical response of rabbit arteries to balloon dilation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Biology of calcification in vascular cells: intima versus media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

The osteoblast: a sophisticated fibroblast under central surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Bone resorption by osteoclasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Biology of RANK, RANKL, and osteoprotegerin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

RANKL-RANK signaling in osteoclastogenesis and bone disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Expression of functional RANK on mature rat and human osteoclasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Structural and functional insights of RANKL-RANK interaction and signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Characterization of structural domains of human osteoclastogenesis inhibitory factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

The mechanism of mineralization and the role of alkaline phosphatase in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Prevalence and progression of peripheral vascular calcification in type 2 diabetes subjects with preserved kidney function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Atherosclerosis — An Inflammatory Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

The role of shear stress in the pathogenesis of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

How hyperglycemia promotes atherosclerosis: molecular mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Are low erythropoietin and 1,25-dihydroxyvitamin D levels indicative of tubulo-interstitial dysfunction in diabetes without persistent microalbuminuria?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Glucose stimulates chondrocyte differentiation of vascular smooth muscle cells and calcification: A possible role for IL-1β.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Regulatory mechanisms in vascular calcification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

TRAIL expression in vascular smooth muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Correction: TRAIL-Deficiency Accelerates Vascular Calcification in Atherosclerosis via Modulation of RANKL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Vascular endothelial responses to altered shear stress: pathologic implications for atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Systemic Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E–Null Diabetic Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Progression of coronary artery calcium predicts all-cause mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Inflammation and the osteogenic regulation of vascular calcification: a review and perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Osteoprotegerin, vascular calcification and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Regulation and function of Rankl in arterial calcification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Osteoprotegerin and mortality in type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Increased osteoprotegerin serum levels in men with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcified human carotid atheroma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Determinants of Progression of Coronary Artery Calcification in Type 2 Diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Relationship between RANKL and neuroendocrine activation in elderly males with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Evaluation of RANKL/OPG Serum Concentration Ratio as a New Biomarker for Coronary Artery Calcification: A Pilot Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Prognostic value of apoptosis markers in advanced heart failure patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Association of serum TRAIL level with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Aortic valvular interstitial cells apoptosis and calcification are mediated by TNF-related apoptosis-inducing ligand.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Vascular calcification: an update on mechanisms and challenges in treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Recombinant osteoprotegerin effects during orthodontic movement in a rat model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Synergistic enhancement of new bone formation by recombinant human bone morphogenetic protein-2 and osteoprotegerin in trans-sutural distraction osteogenesis: a pilot study in dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

A review of denosumab for the treatment of osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Denosumab: a novel antiresorptive drug for osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

TRAIL protects against endothelium injury in diabetes via Akt-eNOS signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Bone mineral crystal size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Pravastatin and olmesartan synergistically ameliorate renal failure-induced vascular calcification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Impact of statins on serial coronary calcification during atheroma progression and regression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Endothelin-1 is a potent regulator in vivo in vascular calcification and in vitro in calcification of vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Phenotypic modulation of vascular smooth muscle cells during medial arterial calcification: a role for endothelin?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Submaximal suppression of parathyroid hormone ameliorates calcitriol-induced aortic calcification and remodeling and myocardial fibrosis in uremic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Vitamin K supplementation and progression of coronary artery calcium in older men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Treatment of cutaneous calciphylaxis with sodium thiosulfate: two case reports and a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Sodium thiosulfate prevents vascular calcifications in uremic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.02.003

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/J.VPH.2016.02.003

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b6nydoymp5aybfmwcwyi7rcs2y

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_b6nydoymp5aybfmwcwyi7rcs2y

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b6nydoymp5aybfmwcwyi7rcs2y

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/b6nydoymp5aybfmwcwyi7rcs2y

1 reference

30 July 2022